Skip to main content
Calliditas Therapeutics logo

Calliditas Therapeutics — Investor Relations & Filings

Ticker · CALTX ISIN · SE0010441584 LEI · 549300PVPZO8TNT76B58 ST Manufacturing
Open in API
Filings indexed 282 across all filing types
Latest filing 2020-06-24 Capital/Financing Update
Country SE Sweden
Listing ST CALTX

About Calliditas Therapeutics

https://www.calliditas.se/en/

Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for rare diseases with significant unmet medical needs. The company concentrates on orphan indications, with an initial focus on renal and hepatic diseases. Its lead product, TARPEYO® (budesonide), is approved in the U.S. for the treatment of primary immunoglobulin A nephropathy (IgAN) and is marketed as Kinpeygo® in Europe. Calliditas is advancing a pipeline of novel medications and seeks strategic partnerships to expand its development and commercialization efforts for therapies addressing conditions with few or no existing approved treatments.

Recent filings

Filing Released Lang Actions
Citigroup meddelar att stabiliseringsåtgärder skett i Calliditas Therapeutics depåbevis som handlas på The Nasdaq Global Select Market
Capital/Financing Update Classification · 99% confidence The document is a press release dated June 24, 2020, issued by Citigroup Global Markets Inc. regarding stabilization measures taken in Calliditas Therapeutics AB's American Depositary Shares (ADS) following its recent listing (Global Offering). The text explicitly details stabilization transactions, including dates, volumes, and prices, conducted under EU Market Abuse Regulation and U.S. securities laws (Reg M, Rule 104). This type of announcement, detailing actions related to the offering, capital structure, and market support following a public offering, most closely aligns with 'Capital/Financing Update' (CAP) or potentially a general 'Regulatory Filing' (RNS). Since it specifically concerns the aftermath of a share offering (Global Offering) and the stabilization activities related to that capital event, CAP is the most precise fit, as it covers financing activities and capital structure changes related to the issuance. It is not an earnings release, an annual report, or a management discussion.
2020-06-24 Swedish
Citigroup notifies that stabilization measures have been undertaken in Calliditas Therapeutics' ADSs traded on The Nasdaq Global Select Market
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated June 24, 2020, issued by Citigroup Global Markets Inc. on behalf of Calliditas Therapeutics AB. The core subject is the notification that 'stabilization measures have been undertaken' regarding Calliditas's American Depositary Shares (ADSs) following its Initial Public Offering (IPO) and Global Offering. Stabilization measures are transactions aimed at supporting the market price of newly issued securities. This activity is directly related to the capital raising and subsequent trading activities following a financing event. While it relates to the offering (CAP), the specific content is a regulatory notification about post-IPO market support activities, which often falls under general regulatory announcements or capital/financing updates. Since the document details the stabilization manager, the offering size, the offer price, and the specific dates/venues of stabilization transactions, it is most closely aligned with Capital/Financing Update (CAP) or a general Regulatory Filing (RNS). Given the explicit focus on the mechanics and execution of post-IPO price support, 'CAP' (Capital/Financing Update) is the most specific fit, as stabilization is an integral part of the offering process. It is not an ER, IR, or 10-K, as it contains no periodic financial results, nor is it a DEF 14A or DVA.
2020-06-24 English
Citigroup meddelar att stabiliseringsåtgärder skett i Calliditas Therapeutics depåbevis som handlas på The Nasdaq Global Select Market
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Citigroup announcing stabilization measures taken in the American Depositary Shares (ADS) of Calliditas Therapeutics AB following its IPO/Global Offering. The text explicitly mentions stabilization transactions, the stabilization period, the offering price, and references EU Market Abuse Regulation (MAR) and U.S. securities laws (Reg M, Rule 104). This type of announcement, detailing actions related to the offering process (like stabilization or over-allotment options), is directly related to capital raising and financing activities. While it is a press release, its core subject matter is the mechanics of the recent share offering and subsequent market support. This fits best under 'Capital/Financing Update' (CAP) rather than a general 'Regulatory Filing' (RNS) or 'Report Publication Announcement' (RPA), as it reports on an active financing event outcome/support mechanism.
2020-06-12 Swedish
Citigroup notifies that stabilization measures have been undertaken in Calliditas Therapeutics' ADSs traded on The Nasdaq Global Select Market
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated June 12, 2020, issued by Citigroup on behalf of Calliditas Therapeutics AB. The core content is a notification regarding the undertaking of 'stabilization measures' in Calliditas's American Depositary Shares (ADSs) following its Initial Public Offering (IPO) on The Nasdaq Global Select Market. It details the stabilization transactions, including dates, quantities, and prices, and explicitly mentions compliance with the EU Market Abuse Regulation 596/2014. This type of announcement, which reports on specific market activities related to a recent offering or capital event, does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). It is a specific regulatory disclosure concerning market operations following a capital raise. Since it is a specific regulatory announcement that doesn't match the other defined categories (like DIRS for insider trading, DIV for dividends, or CAP for the financing event itself), the most appropriate fallback category is Regulatory Filings (RNS), as it is a mandatory disclosure under market abuse rules.
2020-06-12 English
Calliditas Therapeutics prices its initial public offering on The Nasdaq Global Select Market in the United States
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated June 5, 2020, announcing the pricing and details of Calliditas Therapeutics' initial public offering (IPO) on The Nasdaq Global Select Market. Key phrases include 'initial public offering', 'capital increase', 'Global Offering price has been set', 'gross proceeds', and 'Use of Proceeds'. This clearly relates to a fundraising or capital structure change event. Based on the definitions, 'Capital/Financing Update (Code: CAP)' is the most appropriate classification for an announcement detailing the pricing, size, and use of proceeds from an IPO.
2020-06-05 English
Calliditas Therapeutics bestämmer priset inom ramen för börsnoteringen på The Nasdaq Global Select Market i USA
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated June 5, 2020, detailing the pricing of a public offering (börsnoteringen) on The Nasdaq Global Select Market in the USA. It specifies the number of new shares/ADRs being issued, the offering price ($19.50 per ADR), the gross proceeds ($90 million USD), the use of proceeds (funding clinical studies for Nefecon), and provides details on the final prospectus and settlement dates. This content directly relates to fundraising, capital structure changes, and the issuance of new securities in a public offering. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it contains the core financial transaction details.
2020-06-05 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.